The NHS site just says:
"For people under 40 without other health conditions, it's currently advised that it's preferable to have another COVID-19 vaccine instead of the Oxford/AstraZeneca vaccine."
That's to do with the risk of stroke. Going by memory, if you're (female), <40 and with no comorbidities, whilst infection rates are low locally... risk of death from Covid is about 1 in 400,000. For that same individual, the risk of death from AZ vaccine is about 1 in 300,000 - so take a different one for preference.
Yes; when you look at the time frames used.
Point 1: Pfizer is 88% effective against B617 after 2 doses + 2 weeks - that's brilliant, even if it's 5% less than against B117
Point 2: This one's a little confusing. Back in March, the figures for 1 dose of AZ were 70-75% effective after 6 weeks, and not yet plateaued in effect, with 90-95% total effectives after 2doses + 3 weeks being bandied about (but no variant specific; and at that time, 2nd doses of AZ hadn't been handed out yet). Either way, 60% is good but not great.
Point 3: Time frames are all important. As mentioned above, 1 dose of AZ still hadn't reached peak effectiveness after 6 weeks, measuring after 3 weeks gives an idea, but little more than an indication at this point. It would be like declaring a rugby match as done and dusted with the score 3 vs 5 about a quarter of the way through the first half
The 3 week cut-off that has been talked about for vaccines for the last 6 weeks or so has been because when conducting the original research Pfizer and Moderna pulled 3 weeks between doses out of their arses, and tested it at that frequency and found it effective - in reality, it's a random time frame. We need more data; but Point 3 is not a bad thing, just not an ideal thing either.
ETA: As ever, the above is my understanding, and I reserve the right to be wrong; it's still way outside my speciality.